VOLITIONRX LTD 8-K — AI Bull & Bear Analysis

The filing reveals a high-stakes negotiation between VolitionRx and its primary lender following a failure to maintain required market capitalization levels. While the waiver prevents a catastrophic liquidity event, it does so at the cost of increased debt and the creation of a potent dilution mechanism. Investors must now weigh the relief of avoided bankruptcy against the long-term cost of the lender's enhanced ability to convert debt into equity at discounted rates.